AU Patent

AU2017229778A1 — Methods and compositions for inhibiting PMP22 expression

Assigned to Ionis Pharmaceuticals Inc · Expires 2018-08-16 · 8y expired

What this patent protects

The present embodiments provide methods, compounds, and compositions useful for inhibiting PMP22 expression and for treating, preventing, or ameliorating a disease associated with PMP22.

USPTO Abstract

The present embodiments provide methods, compounds, and compositions useful for inhibiting PMP22 expression and for treating, preventing, or ameliorating a disease associated with PMP22.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017229778A1
Jurisdiction
AU
Classification
—
Expires
2018-08-16
Drug substance claim
No
Drug product claim
No
Assignee
Ionis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.